Oversold

LLY

Valuation76/ 100
Cash flow & growth82/ 100
Upside potential77/ 100
Risk potential19/ 100

LLY's valuation is historically cheap, fundamentals are above averages and forward estimates point to improving growth and profitability.

Score change since last week

The score rose 1 point, mainly due to valuation and price changes. Price fell 2.1%, from $1174.61 to $1149.36. Reported EPS was unchanged, so the lower price improved valuation support.

Valuation and price changes added 0.3 points. The comparison uses the same available inputs on both dates. Displayed changes are rounded to whole points.

Valuation

Historical cheapness: current PE is 37.4× versus the full-history median of 48.9× shown in the valuation table, producing 67.5/100. Positive weekly observations receive equal weight; lower past EPS alone does not disqualify them.

Outlook-adjusted valuation: 75.6/100. The model applies a 34.8% earnings-growth assumption and a 10% annual return hurdle, with positive credit limited by evidence coverage and confidence.

Forward price scenarios use recent PE history separately. Recent history has a separately weighted median of 51.8× (18-month half-life). The favorable scenario uses 44.4× PE and $43.2 projected EPS, informed by growth, margins and earnings-quality checks. This is a model scenario, not an analyst target. A return to the full-history median is not assumed.

Cash flow & growth

Business trends are strong. Over the past year: revenue +49.6%, earnings +94.8%, operating margin +1 percentage points. Free cash flow is 25.2% of revenue. The business score is 82.2/100. Growth, margins and cash generation drive the score. Missing or older data receives less weight.

Favorable scenario

Stronger earnings and valuation could support a higher share price.

Our favorable case uses $43.23 of EPS and a 44.4× PE, suggesting a share price of about $1917.95. Valuation history and outlook inform the PE.

The displayed favorable scenario is 71.9% upside, or about $1917.89.

This is a scenario based on our model, not a forecast or probability.

Downside scenario

Weaker than expected earnings could put pressure on the share price.

Our downside case uses $26.12 of EPS and a 34.8× PE, suggesting a share price of about $907.73 — 19% below today’s price. Valuation history and outlook inform the PE.

This is a scenario based on our model, not a forecast or probability.

LLY vs Historical averages

MetricCurrentAverageRelative
PE37x57x35% lower
PE percentile305040% lower
EPS$29.80$9.50214% higher
FCF$20.1B$3.2B525% higher
Loading historical comparisons…

LLY’s earnings and cash flow are above their historical averages, while its earnings multiple is lower.

LLY Forward outlook

MetricOutlook
Forward valuationStrongly improving
Forward earningsStrong growth
Forward revenueGrowth
Forward profitabilityExpanding
Analyst coverageModerate
Estimate dispersionModerate

LLY’s outlook is generally improving, with growth expectations supporting the valuation case.

LLY PE Valuation

Loading pe valuation table…

This table applies LLY's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.

LLY Earnings Per Share

Loading earnings per share…

This chart tracks LLY's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.

LLY Quarterly Revenue

Loading quarterly revenue…

This chart tracks LLY's quarterly revenue over time and shows how sales are changing from year to year.

LLY Free Cash Flow

Loading free cash flow…

This chart tracks LLY's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.

LLY Total Shares

Loading shares over time…

This chart tracks changes in LLY's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.

LLY Net Leverage

Loading net leverage…

Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.

LLY PE vs Healthcare Sector

Loading pe vs sector average…

This chart compares LLY's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.

LLY Weekly Price

Loading weekly price…

This chart uses LLY's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.

LLY Weekly Moving Averages

Loading weekly moving averages…

This chart compares LLY's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.

LLY Yearly ROI

Loading yearly ROI…

Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.

MEDP

Valuation47/ 100
Cash flow & growth75/ 100
Upside potential39/ 100
Risk potential32/ 100

MEDP's valuation appears fair, fundamentals are above averages and the outlook sends mixed signals, though analyst coverage is limited.

Score change since last week

The score fell 3 points, mainly due to valuation and price changes. Price fell 1.6%, from $600.65 to $591.29.

Valuation and price changes subtracted 3.0 points. The comparison uses the same available inputs on both dates. Displayed changes are rounded to whole points.

Valuation

Historical cheapness: current PE is 34.4× versus the full-history median of 32.2× shown in the valuation table, producing 45.5/100. Positive weekly observations receive equal weight; lower past EPS alone does not disqualify them.

Outlook-adjusted valuation: 46.9/100. The model applies a 13% earnings-growth assumption and a 10% annual return hurdle, with positive credit limited by evidence coverage and confidence.

Forward price scenarios use recent PE history separately. Recent history has a separately weighted median of 31.8× (18-month half-life). The favorable scenario uses 33.5× PE and $20.8 projected EPS, informed by growth, margins and earnings-quality checks. This is a model scenario, not an analyst target. A return to the full-history median is not assumed.

Cash flow & growth

Business trends are strong. Over the past year: revenue +24.7%, earnings +26.9%, operating margin -0.4 percentage points. Free cash flow is 26.4% of revenue. The business score is 74.8/100. Growth, margins and cash generation drive the score. Missing or older data receives less weight.

Favorable scenario

Stronger earnings and valuation could support a higher share price.

Our favorable case uses $20.80 of EPS and a 33.5× PE, suggesting a share price of about $697.29. Valuation history and outlook inform the PE.

The displayed favorable scenario is 18.7% upside, or about $697.39.

This is a scenario based on our model, not a forecast or probability.

Downside scenario

Weaker than expected earnings could put pressure on the share price.

Our downside case uses $14.59 of EPS and a 27.5× PE, suggesting a share price of about $401.43 — 32% below today’s price. Valuation history and outlook inform the PE.

This is a scenario based on our model, not a forecast or probability.

MEDP vs Historical averages

MetricCurrentAverageRelative
PE34x33x5% higher
PE percentile625024% higher
EPS$17.07$8.7795% higher
FCF$733.5M$419.1M75% higher
Loading historical comparisons…

MEDP’s earnings and cash flow are above their historical averages, while its earnings multiple is higher.

MEDP Forward outlook

MetricOutlook
Forward valuationImproving
Forward earningsGrowth
Forward revenueStable
Forward profitabilityStable
Analyst coverageLimited
Estimate dispersionTight

MEDP’s outlook is mixed, though analyst coverage is limited.

MEDP PE Valuation

Loading pe valuation table…

This table applies MEDP's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.

MEDP Earnings Per Share

Loading earnings per share…

This chart tracks MEDP's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.

MEDP Quarterly Revenue

Loading quarterly revenue…

This chart tracks MEDP's quarterly revenue over time and shows how sales are changing from year to year.

MEDP Free Cash Flow

Loading free cash flow…

This chart tracks MEDP's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.

MEDP Total Shares

Loading shares over time…

This chart tracks changes in MEDP's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.

MEDP Net Leverage

Loading net leverage…

Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.

MEDP PE vs Healthcare Sector

Loading pe vs sector average…

This chart compares MEDP's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.

MEDP Weekly Price

Loading weekly price…

This chart uses MEDP's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.

MEDP Weekly Moving Averages

Loading weekly moving averages…

This chart compares MEDP's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.

MEDP Yearly ROI

Loading yearly ROI…

Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.